



Cannabidiol modulates hippocampal genes involved in mitochondrial function, ribosome biogenesis, synapse organization, and chromatin modifications


Short Communication

Cite this article: Machado JPD, de Almeida V, Zuardi AW, Hallak JEC, Crippa JA, and Vieira AS. (2024) Cannabidiol modulates hippocampal genes involved in mitochondrial function, ribosome biogenesis, synapse organization, and chromatin modifications. *Acta Neuropsychiatrica* 36:330–336. doi: [10.1017/neu.2024.13](https://doi.org/10.1017/neu.2024.13)

Received: 11 December 2023
Revised: 9 March 2024
Accepted: 20 March 2024
First published online: 26 March 2024

Keywords:
CBD; RNA-Seq; transcriptomics; laser-capture microdissection; hippocampal subfields

Corresponding author:
André S. Vieira; Email: asv@unicamp.br

João P. D. Machado^{1,2}, Valéria de Almeida³, Antonio W. Zuardi^{4,5},
Jaime E. C. Hallak^{4,5}, José A. Crippa^{4,5} and André S. Vieira^{1,2} 

¹Laboratory of Electrophysiology, Neurobiology and Behaviour, Dept Functional and Structural Biology, Institute of Biology, University of Campinas, Campinas, São Paulo, Brazil; ²Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas, São Paulo, Brazil; ³Laboratory of Neuroproteomics, Dept Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, São Paulo, Brazil; ⁴Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil and ⁵National Institute for Science and Technology – Translational Medicine, Rio de Janeiro, Rio de Janeiro, Brazil

Abstract

Background: Cannabidiol (CBD) is one of the main cannabinoids present in *Cannabis sativa* female flowers. Previous investigation has already provided insights into the CBD molecular mechanism; however, there is no transcriptome data for CBD effects on hippocampal subfields. Here, we investigate transcriptomic changes in dorsal and ventral CA1 of adult mice hippocampus after 100 mg/kg of CBD administration (i.p.) for one or seven consecutive days. **Methods:** C57BL/6JUnib mice were treated with either vehicle or CBD for 1 or 7 days. The collected brains were sectioned, and the hippocampal sub-regions were laser microdissected for RNA-Seq analysis. **Results:** The transcriptome analysis following 7 days of CBD administration indicates the differential expression of 1559 genes in dCA1 and 2924 genes in vCA1. Furthermore, GO/KEGG analysis identified 88 significantly enriched biological process and 26 significantly enriched pathways for dCBD7, whereas vCBD7 revealed 128 enriched BPs and 24 pathways. **Conclusion:** This dataset indicates a widespread decrease of electron transport chain and ribosome biogenesis transcripts in CA1, while chromatin modifications and synapse organization transcripts were increased following CBD administration for 7 days.

Significant outcomes

We identified distinct changes in gene expression of CA1 neurons following both single and multiple administrations of cannabidiol (CBD). This highlights the molecular impact of CBD on hippocampal neurons and expands our understanding of its mechanisms of action. We revealed that repeated CBD administration led to a greater number of gene expression alterations compared to a single administration, emphasizing the importance of treatment frequency in modulating gene expression. We found that daily CBD administration for seven days resulted in the downregulation of genes related to energy metabolism and protein synthesis/degradation, while genes involved in chromatin regulation and synapse organization were upregulated. These specific gene expression changes shed light on potential cellular effects and molecular mechanisms underlying CBD actions in the hippocampus.

Limitations

One limitation of this study is its reliance on animal models, specifically C57BL/6JUnib mice, which may not fully reflect human responses to CBD. Additionally, the study primarily investigated the effects of CBD under healthy conditions and did not directly address its therapeutic effects for specific disorders or conditions. Thus, the clinical relevance and applicability of the findings to therapeutic interventions remain to be determined.

© The Author(s), 2024. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology.



Introduction

Cannabidiol (CBD) is a natural compound found in female flowers of *Cannabis sativa*, an ancient plant with a long history of agriculture by humanity (Ren *et al.*, 2021). CBD has a complex pharmacodynamic profile with targets like enzymes, membrane transporters, ionic

receptors, and channels (Bih *et al.*, 2015). Regardless of being a phytocannabinoid and having a structural similarity to Δ^9 -THC, CBD exhibits low affinity to the CB1 receptor orthosteric site (McPartland *et al.*, 2007). This may be a possible explanation for the lack of CBD intoxicating effects. Preclinical research has suggested that CBD may have potential therapeutic effects as an antiepileptic, antioxidant, antipsychotic, and anxiolytic agent (Elsaid *et al.*, 2019). Despite these promising findings, the underlying molecular mechanisms and gene activation associated with CBD in brain cells are still not fully understood. Until recently, almost all countries have strict drug policies and a history of drug-related violence that creates obstacles, restricting access to cannabis, hindering scientific research. These limitations prevent both researchers and patients from fully exploring the potential of cannabis as a treatment option and comprehending the intricate molecular mechanisms and gene activation associated with cannabis compounds, like CBD.

One of the brain regions most affected by a plurality of psychiatric and neurological disorders such as depression, schizophrenia, and epilepsy is the hippocampus (Anand and Dhikav, 2012). The hippocampus is a structure segmented into sub-regions (CA1, CA2, CA3, and DG) that form a complex circuitry involved mainly in learning and memory processes (Fanselow and Dong, 2010; Squire *et al.*, 2015). Each of these sub-regions has distinct molecular mechanisms and neuronal connections, thus selecting cellular populations precisely helps to specifically explore hippocampal functionality (Machado *et al.*, 2022).

In the present study, we used the laser capture microdissection (LCM) in conjunction with RNA-Seq to select particular cell populations, dorsal and ventral CA1, preserving specific expression characteristics of such regions. With these strategies, we explore the effect of CBD on the transcriptome of dorsal and ventral CA1 after intraperitoneal administration for 1 or 7 days.

Methods

Animals, drugs, and tissue processing

Three-month-old males C57BL/6JUnib were housed in a ventilated environment (12 h/12 h light cycle) with *ad libitum* access to standard rodent chow and water. Mice were divided into four groups ($n = 5$): CR1 – 1 day of vehicle (0.15 M NaCl and 2% Tween 80); CBD1 – 1 day of CBD (100 mg/kg); CR7 – 7 days of vehicle (0.15 M NaCl and 2% Tween 80); CBD7 – 7 days of CBD (100 mg/kg). All solutions were prepared with NaCl at 98% and Tween 80 at 2% (Sigma-Aldrich, UK) and administered *i.p.* in a volume of 1 mL/kg. The 100 mg/kg dosage and the treatment duration were based on previous studies demonstrating its efficacy in producing anxiolytic-like effects in rats and mice with high doses and chronic administration (Zanelati *et al.*, 2010; Long *et al.*, 2012; Abame *et al.*, 2021). After 24 hours from the last *i.p.* CBD administration, animals were anaesthetized, brains were collected and processed for laser microdissection as previously described (Machado *et al.*, 2022). The ventral and dorsal CA1 boundaries were located based on previous studies (Fanselow and Dong, 2010) and Allen Brain Atlas *in situ* hybridization markers (<http://portal.brain-map.org/>).

Library preparation, next-generation sequencing, and data processing

RNA was extracted and libraries were prepared as previously described using TruSeq Stranded Total RNA LT (Illumina®, CA,

USA) from 200 ng of RNA (Machado *et al.*, 2022). Pooled libraries were sequenced on a HiSeq® 2500 (Illumina®, CA, USA) in high output mode, generating 100-bp paired-end sequences. On average, 20 million paired-end reads were obtained per sample, totaling 794.682.591 reads across all samples.

We aligned all sequenced reads with the *Mus musculus* genome (GRCm38.96) using the StarAligner 2.6 program (Dobin *et al.*, 2013). The DESeq2 package (Love, *et al.*, 2014) was used to normalize and statistically analyze differentially expressed genes (adjusted p -value < 0.05). Enrichment analysis was performed using clusterProfiler package (Wu *et al.*, 2021) to classify functional profiles into significant (adjusted p -value < 0.05) KEGG pathways and GO terms – biological processes (BPs).

Results

Identification of DEGs and samples visualization

A principal component analysis (PCA) was conducted for dorsal CA1 (dCBD1vsCR1 and dCBD7vsCR7) and ventral CA1 (vCBD1vsCR1 and vCBD7vsCR7) (Figs. 1A–D). Both dorsal and ventral CA1 samples revealed an overlap of the CBD1 and CR1, while the CBD7 and CR7 formed distinct groups. The number of upregulated and downregulated genes is represented in Fig. 1E. For a complete list of differentially expressed genes (DEGs) refer to Supplementary Table 1.

CBD effect on dorsal and ventral CA1

GO/KEGG analysis identified 88 significantly enriched BPs and 26 significantly enriched pathways for dCBD7, whereas vCBD7 revealed 128 enriched BPs and 24 pathways ($p_{\text{adjust}} < 0.05$) (Supplementary Table 2). GO enrichment analysis using upregulated/downregulated genes depicted transcriptional change of biological functions (Fig. 2). In the dCBD1 and vCBD1 groups, only a single significant biological process was observed (Supplementary Table 2).

Discussion

In this study, we used LCM/RNA-Seq to examine gene expression changes in distinct hippocampal neuron subtypes after CBD treatment. We aimed to unveil the CBD impact on transcriptome modifications and pertinent BPs/pathways associated with these changes. Additionally, we aimed to differentiate between effects within different hippocampal regions, dorsal and ventral, across two administration protocols (1-day and 7-day intervals). Our findings revealed, for the first time, a reduction in the expression of several genes linked to the respiratory chain and ribosomal subunits in mice, accompanied by an increase in the expression of genes related to histone regulation. Furthermore, vCA1 exhibited upregulation of neural projection formation genes, while dCA1 showed upregulation of RNA splicing genes. Overall, these results contribute to advancing our knowledge of the CBD effects in hippocampal neuron gene expression.

Administration frequency

Our study reveals a significant difference in the gene expression between the two treatments. Prior research has noted behavioural and molecular distinctions between single and chronic CBD administrations (50 mg/kg) in C57BL/6JArc mice (Long *et al.*, 2010; Darweesh, *et al.*, 2020). CBD treatments for pain, psychiatric




Figure 1. Sample variability and distribution of differentially expressed genes. (A) Principal component analysis of gene expression data from dorsal CBD1. (B) Principal component analysis of gene expression data from dorsal CBD7. (C) Principal component analysis of gene expression data from ventral CBD1. (D) Principal component analysis of gene expression data from ventral CBD7. (E) Barplot displaying the number of differentially expressed transcripts identified in each ventral and dorsal CBD analysis.

disorders, and various other conditions are often administered as a single acute dose, but effective doses may vary across disease states (Britch, *et al.*, 2021). CBD ability to bind to multiple molecular targets may play a role in producing different physiological effects. Furthermore, binding duration is critical in determining the effectiveness and potency of pharmacological responses of several targets affected by CBD affinity and bioavailability.

While some similarities in molecular effects of dosages are observed, there are discrepancies in administration frequency (Long *et al.*, 2010; Valvassori *et al.*, 2013). CBD doses of 60 mg/kg resulted in increased mitochondrial activity in both acute and chronic administration in rats hippocampus and prefrontal cortex (Valvassori *et al.*, 2013). On the other hand, reducing the dosage to 15 mg/kg led to no response in a single dose of CBD, but increased mitochondrial activity in the hippocampus and striatum of the chronic dosage group (Valvassori *et al.*, 2013). Although previous studies have demonstrated similarities and differences, we are the first to report a significant number of differentially expressed genes in two administration frequencies. Therefore, our data clarify that the transcriptome of CA1 neurons undergoes more significant alteration after 7 days of CBD administration than a single dose.

Respiratory chain and TCA cycle

We observed a reduction in transcriptional levels of all mitochondrial respiratory chain complexes in CA1 after administering CBD for 7 days (Figure S1). *In vitro* studies have shown that CBD can reduce oxygen consumption and mitochondrial complex activity (Fišar, *et al.*, 2014; Singh, *et al.*, 2015). However, Valvassori *et al.* (2013) observed an increased mitochondrial complex activity in rats hippocampus after administering CBD (60 mg/kg) for 14 consecutive days. Differences in models, doses, and administration methods account for the variability in CBD effects

on mitochondria. Additionally, reduced respiratory chain complex expression in our data may not imply compromised mitochondrial function due to respiration rate limitations and mechanisms, like a compensatory increase in glycolytic rate (Brand and Nicholls, 2011). Furthermore, another possibility is that CBD administration resulted in reduced energy demand by CA1 neurons, resulting in a reduction in mitochondrial demand and function. Such a possibility is reinforced by the lack of hypoxia and cell death in CA1 that would take place in case of a reduction of mitochondrial functional capacity with no change in neuronal energy demand. However, further experiments are needed to address such a possibility.

The previously mentioned studies show a biphasic CBD effect on mitochondrial respiration. Evidence suggests that CBD enhances mitochondrial respiration at lower or moderate dosages and inhibits it at higher concentrations. This observation highlights CBD dose-dependent impact on mitochondrial function, emphasizing the necessity for additional functional studies on underlying mechanisms. Endogenous and exogenous CB1 ligands induced biphasic *in vitro* changes in mitochondrial complexes (Athanasios *et al.*, 2007). Nevertheless, comparing respiratory chain gene activity and expression levels with different CBD dosages in animal models is crucial to comprehend its mitochondrial effects

We are the first to report a reduced expression of tricarboxylic acid cycle (TCA) genes in CA1 after CBD. It is already known that synthetic cannabinoids inhibit TCA enzymes in pancreatic cancer cells (Dando *et al.*, 2013). However, we only observed a reduction in the genes of isocitrate, succinyl-CoA, succinate, and malate dehydrogenase enzymes. Moreover, TCA cycle metabolites were found reduced in CBD-treated cells (Guard *et al.*, 2022). Therefore, significant TCA enzyme gene expression changes suggest CBD probably influences mitochondrial activity.




Figure 2. Enriched biological processes for differentially expressed genes in CBD7. (A) Top enriched biological processes for upregulated genes in dorsal CBD7. (B) Top enriched biological processes for upregulated genes in ventral CBD7. (C) Top enriched biological processes for downregulated genes in dorsal CBD7. (D) Top enriched biological processes for downregulated genes in ventral CBD7. All displayed biological processes reached an adj. p -value < .05.

CBD inhibits endocannabinoid metabolism enzymes and enhances receptor activation despite its low CB1 receptor affinity (McPartland, *et al.*, 2007). CB1 receptor activation by endocannabinoids reduces gene expression related to mitochondrial biogenesis and oxygen consumption in mice adipocytes (Tedesco *et al.*, 2010). Furthermore, our analysis found enriched BPs related to axon and dendrite formation following a 7-day CBD administration in ventral CA1. Inhibiting the respiratory chain via the endocannabinoid system and reducing ATP production may efficiently regulate high energy synaptic processes such as neurotransmitter release and neuroplasticity (Bénard *et al.*, 2012).

Thus, the reduction in crucial mitochondrial gene expression and increase in synaptic modulation genes might be linked to endocannabinoid signalling and may play a role in CBD ability to reduce seizure frequency in both humans and animal models (Cheung *et al.*, 2019; von Wrede, *et al.*, 2021; Madireddy and Madireddy, 2023). A reduction in energy demand by neurons, possibly linked to a increase in inhibition through enhanced gabaergic activity, could consist in a mechanism responsible for seizure reduction in epilepsy following CBD administration. Furthermore, changes in energy metabolism mediated by CBD administration could take place in other brain regions, such as the medial prefrontal cortex, possibly consisting of a mechanism responsible for CBD effects in anxiety, depression, and schizophrenia. Nevertheless, further investigation is required to uncover the underlying molecular mechanisms and confirm this hypothesis.

Ribosome and proteasome

Cell regulates the rate of protein synthesis by maintaining a balance between ATP consumption and ribosomal transcription (Jakubovic and McGeer, 1972; Murray, *et al.*, 2003). Early studies have shown that $\Delta 9$ -THC application causes a reduction of ribosome number (Hattori, *et al.*, 1972). We are the first to report a significant reduction in gene expression of several ribosomal subunit constituents in CA1 after 7 days of CBD administration (Figure S1). Furthermore, our results also show several proteasome subunits downregulated after 7 days of CBD administration. Reduction in genes involved in the ubiquitin/proteasome system may reflect a lower protein synthesis, as fewer proteins are degraded or modified (Xolalpa *et al.*, 2013). Moreover, genes differentially expressed after a single CBD application (Supplementary Table 2) may explain the observed proteasome effect with repeated administration, considering the link between ubiquitin and proteasome in protein degradation. However, further investigation is required to validate the underlying cellular mechanisms involved in protein synthesis and degradation following CBD administration.

Reduction in gene expression of several ribosomal subunit constituents does not necessarily imply lower synaptic plasticity activity (Rosenberg *et al.*, 2014; Caccamo *et al.*, 2015). Decreased protein synthesis may lead to lower levels of synaptic proteins, promoting the elimination of weaker synapses and strengthening

remaining connections. This reduction can also alter proteins involved in plasticity mechanisms like long-term potentiation (LTP) or long-term depression (LTD). Interestingly, we found in our data some genes involved in the late phase of LTP (Chen *et al.*, 2017). Moreover, reduced expression of regulatory proteins or microRNAs can fine-tune synaptic protein levels and modulate plasticity-related signalling pathways (McClung and Nestler, 2008), resulting in an increase in plasticity-related pathways, which is consistent with our findings. Another point to be considered is that a reduction in overall synaptic protein levels may take place at same time as an increase in specific synapse sub-types, such as Gabaergic synapses. However, further experiments are required to verify such a possibility.

Small GTPases and neuroplasticity

Cannabinoids affect small GTPase signalling through CB1 and CB2 receptors (Kurihara *et al.*, 2006; Duman *et al.*, 2015). We are the first to find altered expression of several genes of regulatory GTPases proteins after CBD repeated administration. Furthermore, Rho family of GTPases regulate postsynaptic density and actin cytoskeleton organization (Stankiewicz and Linseman, 2014). Thus, small GTPase activity influenced by CBD may also be responsible for cytoskeleton and synaptic plasticity alteration, but further research is required.

Our findings reveal that CBD increases gene expression linked to synapse organization and dendrite/axon formation solely in the ventral CA1. We found that CBD increases the gene expression of *Actn1* (*Alpha-actinin-1*), *Flna* (*Filamin-A*), *Synpo* (*Synaptopodin*), *Shank1/Shank2* (*SH3 and multiple ankyrin repeat domains protein*), and *Itsn1* (*Intersectin-1*), which play a role in dendritic spine morphology and postsynaptic density organization (Muñoz-Lasso *et al.*, 2020). Thus, CBD influence on hippocampal neuronal cytoskeleton may modify dendritic morphology and promote circuit plasticity. Additionally, the data presented here demonstrate an increase in guidance molecules expression, such as *Sema4d* (*Semaphorin-4D*), *Sema4f* (*Semaphorin-4F*), *Sema5a* (*Semaphorin-5A*), *Plxn2* (*Plexin-A2*), *Plxnb2* (*Plexin-B2*), and *Nrp2* (*Neuropilin-2*) in the vCA1 after CBD. Interactions like *Sema5d/Plexna2* inhibits excitatory synapses formation in mouse hippocampal cells (Duan *et al.*, 2014). In addition, *Sema4d* infusion into mice CA1 promotes the formation of inhibitory synapses and suppresses seizures in models generating seizures via electrical and chemical stimulation (Acker *et al.*, 2018). The ability of CBD to reduce the number of seizures and increase seizure threshold, particularly in animal models, has been well established (Consroe *et al.*, 1982). Therefore, these findings may offer insights into how CBD regulates molecules responsible for inhibitory/excitatory synapse plasticity in vCA1.

Neuroplasticity defects play a role in mood disorders and diseases pathophysiology (Post, 1992; Dorszewska *et al.*, 2020). A single dose of CBD (30 mg/kg) relieved depressive-like behaviors but did not restore dendritic spine density in vCA1 following stress-induced depression (Ma *et al.*, 2021). However, repeated CBD treatment promotes dendritic spine remodelling in the hippocampus of chronically stressed mice (Fogaça *et al.*, 2018). CB1/CB2 antagonists abolished the remodelling effect, suggesting that endocannabinoid receptors mediate the alteration in synaptic density (Fogaça *et al.*, 2018). Similar to our findings, changes in plasticity and cytoskeleton gene expression were observed exclusively with repeated doses, not with a single dose. Thus, changes in plasticity via gene expression require repeated CBD

administration, while single-dose behavioural effects may relate to brain circuit excitatory/inhibitory balance.

Chromatin regulatory genes

Previous studies emphasize the importance of DNA methylation via DNMTs for neuronal plasticity, including learning and memory (Levenson *et al.*, 2006; Feng *et al.*, 2010). CBD (10 mg/kg) induced antidepressant-like effects and reduced global methylation in prefrontal cortex and hippocampus of mice submitted to forced swimming tests (Sales, *et al.*, 2020). Moreover, CBD effects in DNMT activity are linked to modified DNA methylation levels and antidepressant-like effects (Sales, *et al.*, 2020). Our data indicate increased *Dnmt3a* (*DNA methyltransferase 3A*) expression in both CA1 sub-regions after CBD administration. *Dnmt3a* plays a role in modulating dendritic spine growth and behavioural traits (LaPlant *et al.*, 2010). These findings may indicate that CBD influences synapse organization by upregulating DNMT enzymes but further research is required.

We are the first to provide evidence that CBD regulates the expression of numerous enzymes involved in histone modification. We found several upregulated methyltransferases and demethylases (*Kmt2a*, *Kmt2b*, *Kmt2c*, *Nsd3*, *Kdm2a*, *Kdm4b*, and *Kdm7a*) which control lysine methylation in histone tails (Hyun *et al.*, 2017). Our results show that CBD increases gene expression of chromatin and histone modification transcripts in CA1, shedding light on new players for CBD epigenetic effects.

The role of these enzymes is increasingly associated with cancer (Roy *et al.*, 2014), as well as neurodegenerative diseases (Karpova *et al.*, 2017) and neurodevelopmental disorders (Kim *et al.*, 2017). Moreover, emerging evidence regarding the potential of CBD or other cannabinoids in treating many diseases has also grown (Elsaid *et al.*, 2019; Britch *et al.*, 2021; Iffland & Grotenhermen, 2017). Although the mechanisms by which CBD acts in these diseases are not fully understood, the epigenetic alterations generated by its administration may be a potential target for study to explore CBD cellular effects in disease models and therapeutic application.

In conclusion, the transcriptome data generated here reveal that repeated CBD administration leads to significant modifications in dorsal and ventral CA1 neuronal expression. These results provide evidence for CBD cellular effects and molecular mechanisms under healthy conditions, as well as to understand the potential therapeutic effects of its use. Additionally, new potential signalling pathways and genes that are altered after CBD administration in the CA1 sub-region of mice hippocampus were identified with high statistical confidence. These findings improve our understanding of CBD effects on gene expression and its potential impact on molecular mechanisms in the hippocampus.

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/neu.2024.13>

Acknowledgements. We acknowledge the use of artificial intelligence (AI) tools, specifically OpenAI ChatGPT, to refine the quality of the English language used in the present paper. The original English text from the authors was corrected by the AI tool and was still revised by the authors to ensure accuracy and clarity.

Authors' contribution. João P. D. Machado: Conceptualization, methodology, investigation, visualization, formal analysis, and writing – original draft. Valéria de Almeida: Conceptualization, methodology, formal analysis, and writing – original draft. Antonio W. Zuardi: Conceptualization and methodology. Jaime E. C. Hallak: Conceptualization and methodology. José

A. Crippa: Conceptualization and methodology **André S. Vieira:** Conceptualization, methodology, project administration, supervision, and writing – original draft.

Financial support. This work was supported by grants from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação de Amparo à Pesquisa do Estado de São Paulo, SP, Brazil (FAPESP; grant number 2013/07559-3)

Competing interests. The authors declare they have no conflicts of interest.

Animal welfare ethical. All procedures complied with ethical standards for animal experimentation at the University of Campinas-UNICAMP (Brazilian federal law 11.794 (10/08/2008 - Animal Use Ethics Committee protocol 2903-1).

Ethical standard. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional guides on the care and use of laboratory animals.

References

- Abame MA, He Y, Wu S, Xie Z, Zhang J, Gong X, Wu C and Shen J (2021) Chronic administration of synthetic cannabidiol induces antidepressant effects involving modulation of serotonin and noradrenaline levels in the hippocampus. *Neuroscience Letters* **744**, 135594.
- Acker DWM, Wong I, Kang M and Paradis S (2018) Semaphorin 4D promotes inhibitory synapse formation and suppresses seizures in vivo. *Epilepsia* **59**(6), 1257–1268.
- Anand KS and Dhikav V (2012) Hippocampus in health and disease: an overview. *Annals of Indian Academy of Neurology* **15**(4), 239–246.
- Athanasίου A, Clarke AB, Turner AE, Kumaran NM, Vakilpour S, Smith PA, Bagiokou D, Bradshaw TD, Westwell AD, Fang L, Lobo DN, Constantinescu CS, Calabrese V, Loesch A, Alexander SPH, Clothier RH, Kendall DA and Bates TE (2007) Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. *Biochemical and Biophysical Research Communications* **364**(1), 131–137.
- Bénard G, Massa F, Puente N, Lourenço J, Bellocchio L, Soria-Gómez E, Matias I, Delamarre A, Metna-Laurent M, Cannich A, Hebert-Chatelain E, Mulle C, Ortega-Gutiérrez S, Martín-Fontecha M, Klugmann M, Guggenhuber S, Lutz B, Gertsch Jürg, Chaouloff F, López-Rodríguez Mía L, Grandes P, Rossignol R and Marsicano G (2012) Mitochondrial CB1 receptors regulate neuronal energy metabolism. *Nature Neuroscience* **15**(4), 558–564.
- Brand MD and Nicholls DG (2011) Assessing mitochondrial dysfunction in cells. *Biochemical Journal* **435**(2), 297–312.
- Britch SC, Babalonis S and Walsh SL (2021) Cannabidiol: Pharmacology and Therapeutic Targets. *Psychopharmacology* **238**(1), 9–28.
- Caccamo A, Branca C, Talboom JS, Shaw DM, Turner D, Ma L, Messina A, Huang Z, Wu J and Oddo S (2015) Reducing ribosomal protein S6 Kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer's disease. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* **35**(41), 14042–14056.
- Chen PB, Kawaguchi R, Blum C, Achiro JM, Coppola G, O'Dell TJ and Martin KC (2017) Mapping gene expression in excitatory neurons during hippocampal late-phase long-term potentiation. *Frontiers in Molecular Neuroscience* **10**, 39.
- Consroe P, Benedito MAC, Leite JR, Carlini EA and Mechoulam R (1982) Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. *European Journal of Pharmacology* **83**(3-4), 293–298.
- Dando I, Donadelli M, Costanzo C, Dalla Pozza E, D'Alessandro A, Zolla L and Palmieri M (2013) Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. *Cell death & disease* **4**(6), e664.
- Darweesh RS, Khamis TN and El-Elimat T (2020) The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats. *Naunyn-Schmiedeberg's archives of pharmacology* **393**(10), 1871–1886.
- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M and Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**(1), 15–21.
- Dorszewska J, Kozubski W, Waleszczyk W, Zabel M and Ong K (2020) Neuroplasticity in the pathology of neurodegenerative diseases. *Neural plasticity* **2020**, 4245821.
- Duan Y, Wang S-H, Song J, Mironova Y, Ming G-L, Kolodkin AL and Giger RJ (2014) Semaphorin 5A inhibits synaptogenesis in early postnatal- and adult-born hippocampal dentate granule cells. *ELife* **3**, e04390. DOI: [10.7554/eLife.04390](https://doi.org/10.7554/eLife.04390).
- Duman JG, Mulherkar S, Tu Y-K, X. Cheng J and Tolias KF (2015) Mechanisms for spatiotemporal regulation of Rho-GTPase signaling at synapses. *Neuroscience Letters* **601**, 4–10.
- Elsaid S, Kloiber S and Le Foll B (2019) Effects of cannabidiol (CBD) in neuropsychiatric disorders: a review of pre-clinical and clinical findings. *Progress in molecular biology and translational science* **167**, 25–75.
- Fanselow MS and Dong H-W (2010) Are the dorsal and ventral hippocampus functionally distinct structures? *Neuron* **65**(1), 7–19.
- Feng J, Zhou Y, Campbell SL, Le T, Li E, Sweatt J D, Silva AJ and Fan G (2010) Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. *Nature Neuroscience* **13**(4), 423–430.
- Fišar Z, Singh N and Hroudová J (2014) Cannabinoid-induced changes in respiration of brain mitochondria. *Toxicology Letters* **231**(1), 62–71.
- Fogaça MV, Campos AC, Coelho LD, Duman RS and Guimarães FS (2018) The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling. *Neuropharmacology* **135**, 22–33.
- Guard SE, Chapnick DA, Poss ZC, Ebmeier CC, Jacobsen J, Nemkov T, Ball KA, Webb KJ, Simpson HL, Coleman S, Bunker E, Ramirez A, Reisz JA, Sievers R, Stowell MHB, D'Alessandro A, Liu X and Old WM (2022) Multiomic analysis reveals disruption of cholesterol homeostasis by cannabidiol in human cell lines. *Molecular & Cellular Proteomics* **21**(10), 100262.
- Hattori T, Jakubovic A and McGeer PL (1972) Reduction in number of nuclear membrane-attached ribosomes in infant rat brain following acute 9 - tetrahydrocannabinol administration. *Experimental Neurology* **36**(1), 207–211.
- Hyun K, Jeon J, Park K and Kim J (2017) Writing, erasing and reading histone lysine methylations. *Experimental & Molecular Medicine* **49**(4), e324.
- Ibeas Bih C, Chen T, Nunn AVW, Bazelot M, Dallas M and Whalley BJ (2015) Molecular targets of cannabidiol in neurological disorders. *Neurotherapeutics* **12**(4), 699–730. DOI: [10.1007/s13311-015-0377-3](https://doi.org/10.1007/s13311-015-0377-3).
- Iffland K and Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. *Cannabis and Cannabinoid Research* **2**(1):139–154. DOI: [10.1089/can.2016.0034](https://doi.org/10.1089/can.2016.0034).
- Jakubovic A and McGeer PL (1972) Inhibition of rat brain protein and nucleic acid synthesis by cannabinoids in vitro. *Canadian Journal of Biochemistry* **50**(6), 654–662.
- Karpova NN, Sales AJ and Joca SR (2017) Epigenetic basis of neuronal and synaptic plasticity. *Current Topics in Medicinal Chemistry* **17**(7), 771–793.
- Kim J-H, Lee J, Lee I-S, Lee S and Cho K (2017) Histone lysine methylation and neurodevelopmental disorders. *International Journal of Molecular Sciences* **18**(7), 1404. DOI: [10.3390/ijms18071404](https://doi.org/10.3390/ijms18071404).
- Kurihara R, Tohyama Y, Matsusaka S, Naruse H, Kinoshita E, Tsujioka T, Katsumata Y and Yamamura H (2006) Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. *Journal of Biological Chemistry* **281**(18), 12908–12918.
- Kwan Cheung KA, Peiris H, Wallace G, Holland OJ and Mitchell MD (2019) The interplay between the endocannabinoid system, epilepsy and cannabinoids. *International Journal of Molecular Sciences* **20**(23), 6079. DOI: [10.3390/ijms20236079](https://doi.org/10.3390/ijms20236079).
- LaPlant Q, Vialou V, HE Covington, Dumitriu D, Feng J, Warren BL, Maze I, Dietz DM, Watts EL, Iniguez SD, Koo JW, Mouzon E, Renthal W, Hollis F, Wang H, Noonan MA, Ren Y, Eisch AJ, Bolaños CA, Kabbaj M, Xiao G, Neve RL, Hurd YL, Oosting RS, Fan G, Morrison JH and Nestler EJ (2010)

- Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. *Nature Neuroscience* **13**(9), 1137–1143.
- Levenson JM, Roth TL, Lubin FD, Miller CA, Huang I-C, Desai P, Malone LM and Sweatt JD** (2006) Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. *Journal of Biological Chemistry* **281**(23), 15763–15773.
- Long LE, Chesworth R, Huang X-F, McGregor IS, Arnold JC, Karl T** (2010) A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. *The International Journal of Neuropsychopharmacology* **13**(7), 861–876.
- Long LE, Chesworth R, Huang X-F, Wong A, Spiro A, McGregor IS, Arnold JC and Karl T** (2012) Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice. *PLoS One* **7**(4), e34129.
- Love MI, Huber W and Anders S** (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology* **15**(12), 550.
- Ma H, Li C, Wang J, Zhang X, Li M, Zhang R, Huang Z and Zhang Y** (2021) Amygdala-hippocampal innervation modulates stress-induced depressive-like behaviors through AMPA receptors. *Proceedings of the National Academy of Sciences of the United States of America* **118**(6), e2019409118. DOI: [10.1073/pnas.2019409118](https://doi.org/10.1073/pnas.2019409118).
- Machado JPD, Athie MCP, Matos AHB, Lopes-Cendes I and Vieira A** (2022) The transcriptome of rat hippocampal subfields. *IBRO Neuroscience Reports* **13**, 322–329.
- Madireddy S and Madireddy S** (2023) Therapeutic strategies to ameliorate neuronal damage in epilepsy by regulating oxidative stress mitochondrial dysfunction, and neuroinflammation. *Brain Sciences* **13**(5), 784. DOI: [10.3390/brainsci13050784](https://doi.org/10.3390/brainsci13050784).
- McClung CA and Nestler EJ** (2008) Neuroplasticity mediated by altered gene expression. *Neuropsychopharmacology* **33**, 3–17.
- McPartland JM, Glass M and Pertwee RG** (2007) Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. *British Journal of Pharmacology* **152**(5), 583–593.
- Muñoz-Lasso DC, Romá-Mateo C, Pallardó FV and Gonzalez-Cabo P** (2020) Much more than a scaffold: cytoskeletal proteins in neurological disorders. *Cells* **9**(2), 358. DOI: [10.3390/cells9020358](https://doi.org/10.3390/cells9020358).
- Murray HD, Schneider DA and Gourse RL** (2003) Control of rRNA expression by small molecules is dynamic and nonredundant. *Molecular Cell* **12**(1), 125–134.
- Post RM** (1992) Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. *The American journal of psychiatry* **149**(8), 999–1010.
- Ren G, Zhang X, Li Y, Ridout K, Serrano-Serrano ML, Yang Y, Liu A, Ravikanth G, Nawaz MA, Mumtaz AS, Salamin N, Fumagalli L** (2021) Large-scale whole-genome resequencing unravels the domestication history of *Cannabis sativa*. *Science Advances* **7**(29), eabg2286. DOI: [10.1126/sciadv.abg2286](https://doi.org/10.1126/sciadv.abg2286).
- Rosenberg T, Gal-Ben-Ari S, Dieterich DC, Kreutz MR, Ziv NE, Gundelfinger ED and Rosenblum K** (2014) The roles of protein expression in synaptic plasticity and memory consolidation. *Frontiers in Molecular Neuroscience* **7**, November: 86
- Roy DM, Walsh LA and Chan TA** (2014) Driver mutations of cancer epigenomes. *Protein & Cell* **5**(4):265–96. DOI: [10.1007/s13238-014-0031-6](https://doi.org/10.1007/s13238-014-0031-6).
- Sales AJ, Guimarães FS and Joca SRL** (2020) CBD modulates DNA methylation in the prefrontal cortex and hippocampus of mice exposed to forced swim. *Behavioural Brain Research* **388**, 112627.
- Singh N, Hroudová J and Fišar Z** (2015) Cannabinoid-induced changes in the activity of electron transport chain complexes of brain mitochondria. *Journal of Molecular Neuroscience* **56**(4), 926–931.
- Squire LR, Genzel L, Wixted JT and Morris RG** (2015) Memory consolidation. *Cold Spring Harbor Perspectives in Biology* **7**(8), a021766.
- Stankiewicz TR and Linseman DA** (2014) Rho family GTPases: key players in neuronal development, neuronal survival, and neurodegeneration. *Frontiers in cellular neuroscience* **8**, 314.
- Tedesco L, Valerio A, Dossena M, Cardile A, Ragni M, Pagano C, Pagotto U, Carruba MO, Vettor R and Nisoli E** (2010) Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. *Diabetes* **59**(11), 2826–2836.
- Valvassori SS, Bavaresco DV, Scaini G, Varela RB, Streck EL, Chagas MH, Hallak JEC, Zuardi AW, Crippa JA and Quevedo J** (2013) Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain. *Revista Brasileira de Psiquiatria* **35**(4), 380–386.
- von Wrede R, Helmstaedter C and Surges R** (2021) Cannabidiol in the treatment of epilepsy. *Clinical Drug Investigation* **41**(3), 211–220.
- Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo X and Yu G** (2021) Cluster profiler 4.0: a universal enrichment tool for interpreting omics data. *The Innovation* **2**(3), 100141. DOI: [10.1016/j.xinn.2021.100141](https://doi.org/10.1016/j.xinn.2021.100141).
- Xolalpa W, Perez-Galan P, S. Rodríguez M and Roue G** (2013) Targeting the ubiquitin proteasome system: beyond proteasome inhibition. *Current Pharmaceutical Design* **19**(22), 4053–4093.
- Zanelati TV, Biojone C, Moreira FA, Guimarães FS and Joca SRL** (2010) Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. *British Journal of Pharmacology* **159**(1), 122–128.